Recent advances in cancer therapeutics.
In the past 20 years, cancer therapeutics has undergone a paradigm shift away from the traditional cytotoxic drugs towards the targeting of proteins intimately involved in driving the cancer phenotype. The poster child for this alternative approach to the treatment of cancer is imatinib, a small-molecule kinase inhibitor designed to target chronic myeloid leukaemia driven by the BCR-ABL translocation in a defined patient population. The improvement in survival achieved by treatment of this patient cohort with imatinib is impressive. Thus, the aim is to provide efficacy but with low toxicity. The role of the medicinal chemist in oncology drug discovery is now closely aligned with the role in most other therapeutic areas with high-throughput and/or fragment-based screening, structure-based design, selectivity, pharmacokinetic optimisation and pharmacodynamic biomarker modulation, all playing a familiar part in the process. In this chapter, we selected four areas in which compounds are either approved drugs or in clinical trials. These are chaperone inhibitors, kinase inhibitors, histone deacetylase inhibitors and inhibitors of protein-protein interactions. Even within these areas, we have been selective, particularly for kinase inhibitors, and our aim has been to exemplify newer approaches and novel aspects of medicinal chemistry.
Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, London, United Kingdom.
Nicola
N
Chessum
Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, London, United Kingdom.
Keith
K
Jones
Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, London, United Kingdom.
Elisa
E
Pasqua
Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, London, United Kingdom.
Michael
M
Tucker
D000818:Animals; D056572:Histone Deacetylase Inhibitors / Q000627:therapeutic use; D006801:Humans; D018832:Molecular Chaperones / Q000037:antagonists & inhibitors; D009369:Neoplasms / Q000188:drug therapy*; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use
D056572:Histone Deacetylase Inhibitors; D018832:Molecular Chaperones; D047428:Protein Kinase Inhibitors
Cancer therapeutics; Chaperones; Epigenetics; Histone deacetylases; Kinase inhibitors; Personalised medicine; Protein–protein interactions